CN1763030A - 葛根素衍生物及其医学用途 - Google Patents
葛根素衍生物及其医学用途 Download PDFInfo
- Publication number
- CN1763030A CN1763030A CNA2004100962099A CN200410096209A CN1763030A CN 1763030 A CN1763030 A CN 1763030A CN A2004100962099 A CNA2004100962099 A CN A2004100962099A CN 200410096209 A CN200410096209 A CN 200410096209A CN 1763030 A CN1763030 A CN 1763030A
- Authority
- CN
- China
- Prior art keywords
- puerarin
- ethanoyl
- compound
- acyl group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 90
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 87
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 26
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000006706 cellular oxygen consumption Effects 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 4
- 230000002107 myocardial effect Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 4
- 210000001627 cerebral artery Anatomy 0.000 abstract description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000001817 pituitary effect Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000010812 external standard method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 229960004604 propranolol hydrochloride Drugs 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- -1 ethanoyl puerarin Chemical compound 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 241000219781 Pueraria montana var. lobata Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- PDSVGSZYJOFNPR-UHFFFAOYSA-N 7-chloro-n-[3-(2-nitroimidazol-1-yl)propyl]quinolin-4-amine Chemical compound [O-][N+](=O)C1=NC=CN1CCCNC1=CC=NC2=CC(Cl)=CC=C12 PDSVGSZYJOFNPR-UHFFFAOYSA-N 0.000 description 1
- LWTUZIMLIKOKDI-UHFFFAOYSA-N 7-chloro-n-[3-(2-nitroimidazol-1-yl)propyl]quinolin-4-amine;hydrochloride Chemical compound Cl.[O-][N+](=O)C1=NC=CN1CCCNC1=CC=NC2=CC(Cl)=CC=C12 LWTUZIMLIKOKDI-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102220079670 rs759826252 Human genes 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
No. | 加入量(峰面积) | 检测量(峰面积) | 循环百分比(%) | 平均值(mean)(%) | 相对标准偏差(RSD)(%) |
1 | 710.6 | 636.6 | 89.59 | ||
2 | 695.1 | 645.7 | 92.89 | ||
3 | 346.0 | 318.8 | 92.14 | ||
4 | 355.6 | 328.1 | 92.27 | 92.03 | 1.40 |
5 | 185.2 | 172.7 | 93.25 | ||
6 | 184.6 | 169.9 | 92.04 |
No. | 1 | 2 | 3 | 4 | 5 | 平均 | RSD |
峰面积 | 318.8 | 328.1 | 348.1 | 348.4 | 361.7 | 341.0 | 5.06% |
No. | 1 | 2 | 3 | 4 | 5 | 平均 | RSD |
峰面积 | 645.7 | 636.6 | 610.5 | 542.8 | 562.1 | 599.54 | 7.57% |
参数样品 | t1/2(a)min | t1/2(β)min | CLmg/kg/min/μg/ml | AUC(0-∞(μg/ml)min | T(peak)Min | C(max)μg/ml |
葛根素 | 53.4221±11.3186 | 60.9209±0.4314 | 0.2032±0.0541 | 2729.94±491.99 | 84.91±7.69 | 9.2253±2.3726 |
4ac | 0.1030±0.0163 | 6104.81±275.29 | 51.48±13.03 | 17.6146±2.0624 | ||
5ac | 22.1168±18.7136 | 425.03±253.68 | 0.1011±0.0425 | 4566.95±762.64 | 42.23±18.07 | 15.0431±1.8110 |
6ac | 111.9702±108.66 | 2664.97±379.94 | 0.1696±0.1206 | 3149.69±467.26 | 81.39±10.02 | 4.9324±0.0695 |
组 | 剂量/(g/kg-1) | T波振幅(μV) | |||||
5s 15s 30s 2min 5min10min | |||||||
对照 | 2片/kg | 15.69±7.1716.11±5.30 | 105.23±33.0918.51±9.26** | 66.25±31.9822.10±11.23** | 75.15±27.2930.41±11.58** | 70.62±28.3026.62±10.99** | 19.26±10.1122.09±11.31 |
+ve对照 | |||||||
葛根素 | 0.8 | 18.06±10.09 | 25.69±11.21** | 31.22±14.59** | 39.20±16.11** | 29.10±16.23** | 25.01±10.40 |
4ac | 1.12 | 15.09±7.62 | 23.23±10.69** | 35.40±10.93* | 36.51±16.02** | 25.60±14.23** | 25.41±10.21 |
5ac | 1.20 | 19.09±6.20 | 29.42±9.39** | 37.61±13.43* | 40.11±16.04** | 24.50±13.63** | 24.39±14.28 |
6ac | 1.28 | 16.33±9.18 | 29.09±16.50* | 39.12±15.21* | 41.05±15.60** | 29.14±10.60** | 22.11±9.81 |
Claims (32)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/969,571 US20060084615A1 (en) | 2004-10-20 | 2004-10-20 | Puerarin derivatives and their medical uses |
US10/969,571 | 2004-10-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1763030A true CN1763030A (zh) | 2006-04-26 |
CN100572374C CN100572374C (zh) | 2009-12-23 |
Family
ID=36181532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100962099A Active CN100572374C (zh) | 2004-10-20 | 2004-11-25 | 葛根素衍生物及其医学用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060084615A1 (zh) |
CN (1) | CN100572374C (zh) |
HK (1) | HK1084952A1 (zh) |
WO (1) | WO2006042454A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314677C (zh) * | 2004-11-10 | 2007-05-09 | 山东大学 | 乙酰水杨酰基葛根素衍生物及其制备方法与应用 |
CN1907979B (zh) * | 2006-08-18 | 2010-05-12 | 山东省医学科学院药物研究所 | 8-亚甲基-甲胺-尼泊尔鸢尾异黄酮和以该化合物为活性成分的药物组合物 |
CN101792434A (zh) * | 2010-03-09 | 2010-08-04 | 中山大学 | 一种四酰基葛根素的制备方法 |
CN101805332A (zh) * | 2010-04-30 | 2010-08-18 | 西安力邦制药有限公司 | 葛根素衍生物的制备方法与应用 |
CN102627634A (zh) * | 2012-04-16 | 2012-08-08 | 重庆市中药研究院 | 一种四乙酰葛根素的合成及纯化方法 |
CN104447718A (zh) * | 2014-10-10 | 2015-03-25 | 泸州医学院 | 葛根素磺酸钠的制备及其用途 |
CN107759553A (zh) * | 2012-10-11 | 2018-03-06 | 阿玛纶生物有限公司 | 新型类黄酮化合物及其用途 |
CN108017624A (zh) * | 2016-11-01 | 2018-05-11 | 潘嘉慧 | 葛根素衍生物的结构及其合成方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584909A (zh) * | 2011-01-05 | 2012-07-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种二甲胺基亚甲基取代葡萄糖碳苷异黄酮盐酸盐的制备方法 |
CN103709152B (zh) * | 2013-12-25 | 2016-01-06 | 上海医药工业研究院 | 一种葛根素的分离纯化方法 |
CN105017235B (zh) * | 2015-08-24 | 2017-11-24 | 成都天台山制药有限公司 | 分离纯化葛根素的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541613B2 (en) * | 2000-12-15 | 2003-04-01 | Uyrex Corporation | Isoflavone derivatives |
-
2004
- 2004-10-20 US US10/969,571 patent/US20060084615A1/en not_active Abandoned
- 2004-11-25 CN CNB2004100962099A patent/CN100572374C/zh active Active
-
2005
- 2005-10-12 WO PCT/CN2005/001676 patent/WO2006042454A1/en active Application Filing
-
2006
- 2006-06-23 HK HK06107153A patent/HK1084952A1/xx unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314677C (zh) * | 2004-11-10 | 2007-05-09 | 山东大学 | 乙酰水杨酰基葛根素衍生物及其制备方法与应用 |
CN1907979B (zh) * | 2006-08-18 | 2010-05-12 | 山东省医学科学院药物研究所 | 8-亚甲基-甲胺-尼泊尔鸢尾异黄酮和以该化合物为活性成分的药物组合物 |
CN101792434A (zh) * | 2010-03-09 | 2010-08-04 | 中山大学 | 一种四酰基葛根素的制备方法 |
CN101805332A (zh) * | 2010-04-30 | 2010-08-18 | 西安力邦制药有限公司 | 葛根素衍生物的制备方法与应用 |
CN102627634A (zh) * | 2012-04-16 | 2012-08-08 | 重庆市中药研究院 | 一种四乙酰葛根素的合成及纯化方法 |
CN107759553A (zh) * | 2012-10-11 | 2018-03-06 | 阿玛纶生物有限公司 | 新型类黄酮化合物及其用途 |
CN104447718A (zh) * | 2014-10-10 | 2015-03-25 | 泸州医学院 | 葛根素磺酸钠的制备及其用途 |
CN108017624A (zh) * | 2016-11-01 | 2018-05-11 | 潘嘉慧 | 葛根素衍生物的结构及其合成方法 |
Also Published As
Publication number | Publication date |
---|---|
HK1084952A1 (en) | 2006-08-11 |
US20060084615A1 (en) | 2006-04-20 |
CN100572374C (zh) | 2009-12-23 |
WO2006042454A1 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110382503A (zh) | 制备acc抑制剂及其固体形式的方法 | |
CN1238454A (zh) | 化合物及其用途 | |
JP4038337B2 (ja) | ガルドスチャンネル拮抗物質 | |
CN1763030A (zh) | 葛根素衍生物及其医学用途 | |
FI89479C (fi) | Foerfarande foer framstaellning av ett terapeutiskt anvaendbart 5-rs-racemiskt eller 5-r-optikst aktivt oxazolidin-2-onderivat | |
KR102442536B1 (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
CN1944448A (zh) | 葛根素衍生物及其药物用途 | |
CN110372557B (zh) | 环己烷胺类d3/d2受体部分激动剂 | |
CN113072484A (zh) | 含有琥珀酸酯的磺胺苯甲酰胺类化合物及其制备方法与应用 | |
CN1111631A (zh) | 含3-苯磺酰基-3,7-二氮杂双环[3,3,1]壬烷的药物 | |
CN100341495C (zh) | 格列本脲固体分散体、口服组合物及其制备方法 | |
CN1814616A (zh) | 黄杨碱、黄杨碱盐酸盐及其制备方法和制成的制剂 | |
KR20230058112A (ko) | Ssao 억제제의 다형체 | |
CN1059444C (zh) | 一种防治心血管病的番红花甙的提取方法 | |
RU2735524C2 (ru) | Энантиомер замещенной фенилпропионовой кислоты и способ его получения, его композиция и применение | |
CA3137191A1 (en) | Crystal form s4 of the plk4 inhibitor (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6-yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate | |
CN1251693C (zh) | 一种中西药复方制剂及其制备方法 | |
CN1301253C (zh) | 五元硫杂环类化合物及其用于制备治疗和预防肥胖相关疾病的药物的用途 | |
CN114933584B (zh) | 一种二氢-2h-异吲哚酯类化合物 | |
CN1063690A (zh) | 新的水甘草碱衍生物,含有该类化合物的药物组合物及其制备方法 | |
EA044843B1 (ru) | Кристаллическая форма ингибитора plk4 | |
CN106478616A (zh) | 一种gpr40激动剂的结晶形式及其制备方法 | |
KR20240067878A (ko) | 피라졸로피리미딘 에스테르 화합물 | |
CN1049346A (zh) | 原儿茶醛的糖类衍生物 | |
CN107174586B (zh) | 以芦竹碱衍生物为活性成分的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1084952 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1084952 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: THE HONG KONG POLYTECHNIC UNIVERSITY Free format text: FORMER OWNER: CHINA HONG KONG JOCKEY CLUB INSTITUTE OF CHINESE MEDICINE LIMITED Effective date: 20120604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120604 Address after: Hongkong China Hung Hom Kowloon Hong Kong Polytech University Patentee after: Hong Kong Polytech University Address before: Hongkong, China Patentee before: Hongkong Jockey Club Chinese Medicine Research Institute Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: Kowloon, Hongkong, China Patentee after: The Hong Kong Polytechnic University Address before: Hongkong China Hung Hom Kowloon Hong Kong Polytech University Patentee before: The Hong Kong Polytechnic University |
|
CP02 | Change in the address of a patent holder |